They've got $70 million, two guys named Ned, and plans to go after early-stage science where other venture capital firms ...
Merck's subcutaneous version of Keytruda succeeded in Phase 3 trials, showing non-inferior results to its IV counterpart. The ...
Incyte’s $750 million buyout of Escient Pharmaceuticals is in a rough patch as a mid-stage chronic hives candidate was ...
Synapticure, a startup building digital health tools for people with neurodegenerative conditions and their caregivers, has ...
Efforts by the pharmaceutical industry to expand access to low- and middle-income countries need to be “vastly ...
Therapists can’t be around for their patients 24/7. One startup is betting AI can be the solution. When trained with clinical ...
Biogen and UCB on Tuesday shared an expanded dataset for their Phase 3 lupus program, which they said two months ago ...
Regenxbio reported improved muscle function in boys with Duchenne muscular dystrophy using their gene therapy RGX-202. The ...
Alnylam's nucresiran showed promising results in Phase 1 trial for rare cardiomyopathy, achieving up to 96% TTR reduction at ...
New hepatitis D treatment data from Vir Biotechnology and Bluejay Therapeutics shows promising results in reducing viral levels. Both companies plan further trials, with Vir targeting Phase 3 in 2025.
Rocket Pharmaceuticals reported Monday that benefits from its Danon disease gene therapy were seen up to around five years after treatment.
CSL Behring is closing its Pasadena R&D site, relocating operations to Waltham, Massachusetts, affecting 30 employees. The company is deprioritizing ex vivo lentiviral gene therapy work and focusing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback